Switch theme
Sign up to access all valuation multiples
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
n/a
LTM Revenue n/a
LTM EBITDA n/a
$28.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Captor Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Captor Therapeutics achieved revenue of $3.5M and an EBITDA of -$17.3M.
Captor Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Captor Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.4M | $3.5M | XXX | XXX | XXX |
| Gross Profit | $0.9M | $1.9M | XXX | XXX | XXX |
| Gross Margin | 35% | 54% | XXX | XXX | XXX |
| EBITDA | -$7.6M | -$17.3M | XXX | XXX | XXX |
| EBITDA Margin | -311% | -491% | XXX | XXX | XXX |
| Net Profit | -$8.7M | -$9.6M | XXX | XXX | XXX |
| Net Margin | -356% | -272% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 30, 2025, Captor Therapeutics's stock price is PLN 32 (or $9).
Captor Therapeutics has current market cap of PLN 149M (or $39.8M), and EV of PLN 106M (or $28.2M).
See Captor Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $28.2M | $39.8M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of April 30, 2025, Captor Therapeutics has market cap of $39.8M and EV of $28.2M.
Captor Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Captor Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Captor Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $28.2M | XXX | XXX | XXX |
| EV/Revenue | 8.0x | XXX | XXX | XXX |
| EV/EBITDA | -1.6x | XXX | XXX | XXX |
| P/E | -2.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCaptor Therapeutics's NTM/LTM revenue growth is n/a
Captor Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Captor Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Captor Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Captor Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 44% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -491% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 128% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 122% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 491% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 605% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Captor Therapeutics acquired XXX companies to date.
Last acquisition by Captor Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Captor Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is Captor Therapeutics headquartered? | Captor Therapeutics is headquartered in Poland. |
| Is Captor Therapeutics publicy listed? | Yes, Captor Therapeutics is a public company listed on WAR. |
| What is the stock symbol of Captor Therapeutics? | Captor Therapeutics trades under CTX ticker. |
| When did Captor Therapeutics go public? | Captor Therapeutics went public in 2021. |
| Who are competitors of Captor Therapeutics? | Similar companies to Captor Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Captor Therapeutics? | Captor Therapeutics's current market cap is $39.8M |
| What is the current revenue growth of Captor Therapeutics? | Captor Therapeutics revenue growth between 2023 and 2024 was 44%. |
| Is Captor Therapeutics profitable? | Yes, Captor Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
